Cassava Sciences: Draw back From Alzheimer’s Outcomes Potential Regardless of Developments (SAVA)
This text was written byComply withScientist and dealer of biotech inventory. Concentrate on buying and selling round occasions akin to ...
Monday, May 5, 2025
Tag: Alzheimers
Alzheimer’s Replace and Late Winter Miscellany
The bit of stories that prompted this explicit revisiting of the Alzheimer’s illness scene was the promising chance {that a} ...
Eli Lilly Alzheimer’s drug to face U.Okay. rejection (NYSE:LLY)
travellinglight/iStock by way of Getty Photographs Shortly after a U.Okay. watchdog declined to endorse Biogen's (NASDAQ:BIIB) Alzheimer's drug Leqembi to ...
Voyager: Alzheimer’s Medical Trial Begin (VY-TAU01) Strengthens Funding Thesis (VYGR)
koto_feja/E+ by way of Getty Pictures Thesis Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a biotechnology firm within the medical stage, which ...
Cassava Sciences: Where Did All The Mild Alzheimer’s Disease Patients Go? (NASDAQ:SAVA)
Shidlovski/iStock via Getty Images Cassava Sciences (NASDAQ:SAVA) recently presented a chart at the Alzheimer’s and Parkinson’s Diseases Conference in Lisbon ...
Cassava Sciences again under scrutiny over Alzheimer’s drug research
hapabapa A lab run a City University of New York (CUNY) scientist with ties to Cassava Sciences (NASDAQ:SAVA) and its ...
Vigil Neuroscience study for Alzheimer’s drug to proceed with FDA restrictions (VIGL)
Iryna Drozd Vigil Neuroscience (NASDAQ:VIGL) said the FDA is allowing a Phase 1 clinical trial for its Alzheimer’s drug candidate ...
Promising new Alzheimer’s drugs may benefit whites more than Blacks By Reuters
5/5 © Reuters. A sign is pictured outside of the Emory University Brain Health Center in Atlanta, Georgia, U.S., July ...
Alzheimer’s diagnosis revamp embraces rating scale similar to cancer By Reuters
© Reuters. FILE PHOTO: Dr. Seth Gale points out evidence of Alzheimer?s disease on PET scans at the Center for ...
US to require patient data for payment of Leqembi, similar Alzheimer’s drugs By Reuters
© Reuters. FILE PHOTO: The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January ...
RECOMMENDED
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.